SEO for Longevity, Peptide Therapy & IV Therapy Clinics.
Longevity patients don't search "longevity clinic." They search "peptide therapy near me," "BPC-157," "NAD+ IV," "exosomes for joints." They've read Peter Attia, they've listened to Ben Greenfield, they know more about your service menu than your own front desk. Our SEO program is built for this patient — modality-first content architecture, FDA-peptide-compliance tracking, and content depth that respects how much this audience already knows.
$5,000/mo retainer floor · Calendly-first booking · Founder reviews every inquiry personally.
Monthly patient searches — longevity category
~11,300
peptide therapy near me (5,400), longevity medicine (1,900), IV therapy clinic (1,000), longevity clinic (880), and rising variants
"Peptide therapy near me" search growth
Near-zero → 5,400
the fastest-rising subvertical search term in our data — most of that growth has come since 2022 as peptide therapy entered mainstream health conversation
FDA-restricted compounded peptides since 2024
10+ substances
BPC-157, thymosin alpha-1, CJC-1295, ipamorelin and others moved to Category 2 or outright restriction. Content that doesn't track the FDA status is a liability.
Your patient is searching molecules. Your website is pitching clinics.
In every other subvertical we cover, patients search for the clinic category — "hormone clinic," "med spa," "weight loss clinic." Longevity breaks that pattern. The patient running a search in this category almost never types "longevity clinic near me" (880 monthly searches, globally). They type "peptide therapy near me" (5,400), "NAD+ IV therapy [city]," "BPC-157 clinic," "exosomes for joint pain," "Thymosin alpha-1 provider." The search is a molecule, a modality, a specific protocol. The clinic category is almost invisible in the search data.
A generalist agency runs the standard "longevity clinic SEO" playbook — ranks the homepage, builds a couple of service pages, calls it done — and ends up ranking for 880-monthly-search queries while the 11,000+ monthly modality searches go to whichever site actually has a dedicated BPC-157 page. We build modality-first. Every peptide your clinic offers gets its own page. NAD+ gets a page. Exosomes get a page. Methylene blue gets a page if you do it. The patient search lands on the molecule, the content walks them into your clinical framework, the CTA routes to a consult.
The second complication: FDA has been active. In 2023-2025 the FDA tightened the rules around compounded peptides, moving BPC-157, thymosin alpha-1, CJC-1295, ipamorelin and others to Category 2 or outright restriction. Which peptides your clinic can legally prescribe depends on the current FDA status, your compounding pharmacy relationship, and state-board rules. Content that was accurate in 2022 may now be actively creating legal exposure. Our program includes FDA-status tracking as a standing deliverable — we watch the list, flag content that's gone stale, and rewrite on the month it changes.
The third complication: this patient already knows the material. Longevity patients have often read the primary research on mTOR, autophagy, senescent-cell clearance, NAD+ metabolism. Over-simplified content — the kind a generalist agency would write for a dentist or a plumber — reads as condescending and loses them. The content has to be written at the patient's reading level, which is high. That takes a senior medical writer with a working vocabulary in the science. Most agencies don't have one.
Modality-first architecture, FDA-status-aware content, biohacker-ecosystem integration.
A longevity SEO program has to do three things most healthcare SEO programs don't: target modalities not clinic categories, track FDA peptide status as a live compliance input, and integrate with the biohacker content ecosystem (podcasts, Substacks, LinkedIn practitioner networks) that drives discovery in this segment. Here's how each layer works.
Modality-first content architecture
One dedicated service page per peptide, IV protocol, and specialty modality your clinic offers — BPC-157, thymosin alpha-1, semaglutide (if offered here), CJC-1295, ipamorelin, NAD+ IV, methylene blue, exosomes, PRP, stem cell (where legal), myer's cocktail variants. Each page targets the modality as the primary keyword and routes to a consult CTA.
FDA peptide-status tracking
Standing monthly process: we monitor the FDA's Category 1 / Category 2 / restricted peptide list, cross-reference against what your clinic currently offers, and flag content that needs rewriting when the status changes. This is a compliance-risk deliverable most agencies don't even know to offer.
Biohacker-ecosystem integration
Longevity patients discover clinics through podcasts (Huberman, Attia, Asprey, Greenfield, Rhonda Patrick), Substacks, and LinkedIn practitioner networks more than through Google autocomplete. We integrate content placement into this ecosystem — guest essays, podcast-interview booking support, LinkedIn thought leadership for your provider — so the funnel's top isn't entirely Google-dependent.
Content written at the patient's reading level
Longevity patients read primary research. Our content is written by senior medical writers who can work in the vocabulary of mTOR, autophagy, senescent cells, and mitochondrial dynamics without either dumbing down or bluffing. Shallow content underperforms here by a factor of 3-4 on engagement and 2-3 on booking conversion.
Multi-modality stacked service pages
Most longevity patients buy bundled programs (hormone + peptide + IV + lifestyle coaching), not individual modalities. Our content architecture supports both — individual modality pages capture the modality-search patient, while bundle / program pages capture the "I want a longevity protocol" patient. Internal linking binds them.
Provider-credentials architecture for a skeptical audience
Longevity patients know that the category attracts quackery. Provider credentials — real training, real fellowship, real clinical reasoning — matter more here than in any other subtype. Provider profile pages are built to answer the skeptical reader's question ("is this a real doctor or a supplement influencer?") with depth and specificity.
Four category-specific patterns a standard SEO playbook doesn't handle.
Longevity clinics rarely get the SEO they deserve — partly because the category is new, partly because generalist agencies don't track the FDA peptide landscape, partly because the patient's reading level is higher than most agencies write to. Four specific patterns separate a competent longevity SEO program from one that ranks for the wrong things.
Molecule-name queries out-rank category queries 10-to-1
"BPC-157" (1,300 mo) vs. "longevity clinic" (880 mo). "NAD+ IV" (2,900 mo) vs. "longevity medicine" (1,900 mo). "Semaglutide peptide" vs. "anti-aging clinic." The search-volume math is strongly against a category-only content strategy and strongly in favor of a modality-first one. We build the architecture to match.
FDA status changes mid-program
A peptide that's freely marketable in January can be restricted by June. We monitor the FDA's 503A and 503B compounding lists and the relevant FDA warning-letter stream. When a peptide your clinic markets gets restricted, we have 30-60 days to rewrite or retire the page. Most agencies don't even know this is happening; the first they hear about it is a warning letter.
Podcast and Substack placement outperforms traditional link building
The backlinks that actually move rankings in this subvertical come from the biohacker-ecosystem — appearances on Attia's Drive, Huberman Lab, Asprey's Bulletproof Radio, Rhonda Patrick's FMF, or in Substacks like Ben Greenfield or Dr. Anthony Gustin. A single podcast mention beats 20 generic medical-directory links. Our outreach reflects this.
Informed-patient content needs a medical writer, not a copywriter
A longevity service page has to discuss mechanisms of action, dose ranges, clinical evidence, and known risks — all accurately, all cited. This is medical-grade writing, not marketing copy. Our content team includes senior medical writers with scientific training; a generalist marketing writer cannot produce this at quality.
Modality audit → peptide-status audit → content build → ecosystem integration.
The sequence leads with a modality audit because most longevity accounts have an offering list that's grown faster than their content has. Then comes the FDA peptide-status audit (usually revealing 1-3 pages that need immediate rewriting). Then the content build, then the ecosystem integration work that does most of the link-building lift.
- Step 01
Discovery + modality inventory
30-minute discovery plus an inventory of every modality your clinic currently offers, maps to patient-search volume for each, and identifies the content-vs-offering gap. Typical output: you offer 14 modalities, the site has dedicated content for 4.
- Step 02
FDA peptide-status audit
Cross-reference every peptide on your menu against current FDA Category 1 / 2 / restricted lists and recent warning letters. Flag content that's making claims or implying availability that's no longer compliant. Rewrite or retire in the first 30 days.
- Step 03
Modality-first content build
Dedicated service page per modality you legally offer, written by senior medical writers at the patient's reading level. Mechanism of action, clinical evidence (cited), protocol ranges, known risks, CTA to consult. Typical volume: 10-16 pages in the first 90 days.
- Step 04
Program / bundle page architecture
Alongside the modality pages, a small set of program / bundle pages for patients who want the stacked longevity protocol rather than a specific molecule. These convert at higher rates for the "I want a longevity strategy" buyer; individual modality pages convert better for the "I want BPC-157" buyer.
- Step 05
Biohacker-ecosystem integration
Podcast-booking outreach, Substack guest-essay pitching, LinkedIn thought-leadership rhythm for your provider. This isn't traditional SEO outreach — it's how longevity patients actually discover clinics. Monthly cadence on each channel, with editorial support from our team.
- Step 06
Monthly FDA watch + content refresh
Ongoing monthly review that includes FDA-status re-check, podcast-ecosystem pitch cadence, and content refreshes against emerging modalities (the vertical is new enough that new modalities enter the mainstream every quarter). The program is structurally more alive than a standard SEO engagement.
Modality-page ranking, ecosystem placements, and protocol-enrolled patients.
Longevity patients almost always commit to a program rather than a single visit, so the revenue metric that matters is enrolled patients, not booked consults. We report on modality-page ranking (the top-of-funnel signal), ecosystem placements (the authority signal), and enrolled-patient conversion (the economic signal).
Modality-page ranking across your service menu
Tracked per modality — your BPC-157 page's rank, your NAD+ IV page's rank, your exosomes page's rank, etc. Modality-page ranking is the single best predictor of new-patient flow in this vertical.
Ecosystem placements (podcast / Substack / LinkedIn)
Tracked separately from traditional link count. A Huberman Lab mention and a LinkedIn essay with 50k views are both "one placement" but carry much more signal than raw backlink numbers. We log them, track referral traffic, and measure branded-search lift from each.
Protocol-enrolled patients (not just booked consults)
The revenue metric. A booked consult that doesn't enroll in a protocol is a lost sale; an enrolled patient represents annual-cycle revenue. We report enrolled-patient count monthly with CRM-level source attribution.
FDA-status content coverage
Internal compliance metric: percentage of your peptide-related pages that reflect current FDA status vs. stale 2022-2023 language. Target is 100%; most accounts we take over start at 30-60%.
Illustrative metrics. Individual clinic results vary by market, intake capacity, and baseline. No guaranteed outcomes — standard FTC endorsement disclaimers apply.
Four active regulatory fronts for peptide and longevity marketing in 2026.
The longevity subvertical has the most active regulatory picture in our Phase-2 set. The FDA has been moving against compounded peptides since 2023. The FTC has been active on longevity-claim substantiation. State boards are inconsistent about what a provider can legally offer. State compounding-pharmacy rules are tightening. A content strategy written for the 2022 landscape is partially illegal by 2026.
Four active surfaces we audit on every engagement. Each one is a real liability if the content doesn't reflect current rules.
FDA compounded-peptide Category 2 restrictions
BPC-157, thymosin alpha-1, CJC-1295, ipamorelin and others moved to Category 2 (restricted compounding) in 2023-2025. Content that implies broad availability or clinical equivalence to FDA-approved products is exposed. We rewrite to the current status and watch the list.
FTC Section 5 on longevity-outcome claims
"Extend lifespan," "reverse biological age," "slow aging" — all require scientific substantiation. Longevity is one of the FTC's most actively-policed categories. We rewrite to substantiated language and maintain citation density on every claim.
State medical board scope on longevity medicine
There is no board specialty for longevity medicine. States vary on what a provider can call themselves and what modalities they can offer. We verify provider scope by state and make sure the content doesn't imply credentials that don't exist.
Compounding pharmacy relationship disclosures
Clinics prescribing compounded peptides through a specific 503A or 503B pharmacy are subject to that pharmacy's compliance posture. Content should not imply a compound is FDA-approved when it's being sourced from a compounding pharmacy. We audit every compounded-product page for this.
Common questions.
- Our patients search by peptide name, not by "longevity clinic." Should our SEO reflect that?
- Yes, decisively. Our data shows "peptide therapy near me" at 5,400 monthly searches, individual peptide names (BPC-157, NAD+, thymosin alpha-1) in the hundreds to low-thousands each, and "longevity clinic" at about 880. The modality-search volume is an order of magnitude larger than the category-search volume. A longevity site that only ranks for "longevity clinic" and "longevity medicine" is missing 80%+ of its addressable search volume. Modality-first content is the whole game.
- The FDA restricted several peptides in 2024. Can we still market them?
- Depends on the specific peptide, your clinic's sourcing, and your state's rules. BPC-157 and thymosin alpha-1 moved to Category 2 (restricted compounding) — marketing language has to reflect that they're no longer freely available and cannot be implied as FDA-approved. CJC-1295 and ipamorelin status has shifted. Some clinics have ceased offering certain peptides entirely; others have shifted sourcing. Our content strategy adapts to whichever posture your clinic is running — but we won't let content ship that's materially behind the current FDA status.
- How do we compete with the national longevity brands (Function, InsideTracker, Wild Health, Fountain Life)?
- On clinical relationship and local physical presence. National longevity platforms run impressive at-home testing and telehealth funnels but can't offer in-person IV therapy, in-clinic peptide injection, or provider-led protocol tuning. Your SEO should surface the specific clinical capabilities the national brands can't match — in-person phlebotomy, same-provider continuity, ongoing monitoring with the same physician. Our content positions this advantage explicitly on comparison pages and through provider-led content.
- Should we write content for BPC-157 even if we can't prescribe it right now?
- Only carefully. If your clinic currently cannot legally prescribe BPC-157, a page that reads like a marketing pitch for it creates both an FDA liability and a consumer-protection issue (patients who book expecting it won't get it). A neutral, educational page that explains the current status of BPC-157 and what peptides your clinic CAN offer can still rank for the search term and route the patient to an available alternative. We write to that line, not to a pitch.
- What's the single best link-building move for a longevity clinic?
- A podcast appearance on a major longevity or biohacker show. A single Huberman Lab, Peter Attia Drive, Ben Greenfield Life, Bulletproof Radio, or FMF (Rhonda Patrick) appearance delivers more referral traffic, branded-search lift, and authority signal than dozens of traditional backlinks. The second-best move is a regular LinkedIn writing cadence from your lead provider — LinkedIn is where longevity practitioners read each other and where patients with high disposable income discover clinics. Our link-building effort in this subvertical weights heavily toward both.
- Our provider is a real doctor but doesn't have a longevity-specific fellowship. Does that hurt us?
- Not necessarily. There's no board-recognized longevity specialty — no one does. What matters is that the provider's actual credentials, scope, and clinical approach are visible and verifiable. An internal medicine MD with functional-medicine training can present credibly as a longevity physician if the content is honest about what they are. Patients who are looking for credentials can see the real ones; claims of credentials that don't exist are where clinics get in trouble.
- How long does a longevity SEO program take to produce results?
- Modality-page rankings can move fast — some peptide pages rank in 60-90 days because the SERP is less saturated than mainstream healthcare. Ecosystem placements (podcasts, Substacks) are harder to schedule and typically take 3-6 months to land. Enrolled-patient lift is 6-9 months out because the research cycle is long. We report the leading indicators (modality rankings, podcast pitches sent / accepted, branded search volume) through the early months so the program's trajectory is visible before enrolled-patient numbers move.
Pair this with the rest of the six-surface playbook.
The paired page
Meta Ads for Hormone & Wellness Clinics (hub)
The paid-social side — Facebook and Instagram campaigns for the longevity vertical. Meta is a supporting channel here because biohacker discovery runs through podcasts and Substacks more than Meta; the paid-social program is built accordingly. Dedicated longevity Meta Ads page ships in Sprint 4.
Ready to rank for the molecules your patients actually search?
Book a 30-minute discovery call. We'll pull your clinic's current modality inventory against the FDA peptide list and search-volume data, and show you the three modality pages that would produce the fastest ranking lift — whether you hire us or not.